Related to this topic: Leaflets | Patient+ | UK Guidelines | Online Videos | Weblinks | Equipment | Books | Your Experience | Other resources | Glossaries
Print options: Printer friendly version of this leaflet (html)     Other options:  AddThis Social Bookmark Button (what's this?)

PatientPlus articles are written for doctors and so the language can be technical. However, some people find that they add depth to the articles found in the other sections of this website which are written for non-medical people.

Peptic Ulcer Disease

Description

The term peptic ulcer refers to both gastric and duodenal ulcers. Important aetiological factors include Helicobacter pylori, NSAIDs, acid and pepsin. Other important factors include smoking, alcohol, bile acids, aspirin, steroids and stress. Defence mechanisms include mucus, bicarbonate, mucosal blood flow and prostaglandins.

When broadly defined, dyspepsia occurs in 40% of the population annually,1 leads to a consultation with a GP in 5% and endoscopy in 1%. Of those who receive endoscopy, about 40% have functional or non-ulcer dyspepsia, 40% have gastro-oesophageal reflux disease and 13% have ulcer disease. Gastric cancer is found in just 2% with oesophageal cancer in a further 1%.

Epidemiology

In the past, duodenal ulcer was 10 times as common in men as women and gastric ulcer had a male preponderance of 3:2. Now the frequency is much less, largely because of H pylori eradication and the sex incidence is more even. The period prevalence of peptic ulceration in British General Practice has decreased markedly, especially among younger people and those from more deprived areas. The annual age-standardized period prevalence of peptic ulceration decreased from 3.3/1000 in 1994 to 1.5/1000 in 1998 for men, and from 1.8/1000 to 0.9/1000 for women.2 Current trends are for a decreasing incidence in young men and an increasing number in older women.

Emergency admission rates for duodenal and gastric ulcer for complications or severe pain have shown remarkably little change over the last three decades. In contrast, elective surgery has declined dramatically, as a result of advances in treatment but also from changes in the natural history.3

Presentation

Symptoms

Symptoms of dyspepsia are very non-specific and diagnosis is unreliable on history alone.

  • Epigastric pain, usually 1 to 3 hours post-prandial. It may sometimes awake the patient in the night and be relieved by food.
  • Nausea.
  • Oral flatulence, bloating, distension and intolerance of fatty food. The last is also associated with gallstones. The other symptoms are caused by aerophagy and sometimes the patient can be seen swallowing air.
  • Heartburn can sometimes occur although it is more typically associated with gastro-oesophageal reflux
  • A posterior ulcer may cause pain radiating to the back if it is penetrating.
  • Symptoms are relieved by antacids but this is very non-specific.

In Taiwan, silent peptic ulcer disease is not uncommon 4 but in Western countries this is unusual.

Signs

In uncomplicated cases there is very little to find on examination.

  • There is often some epigastric tenderness.
  • If gastric emptying is slow, there may be a succussion splash.
Differential diagnosis
Investigations
  • FBC may show evidence of iron deficiency anaemia if there has been significant bleeding but usually it is normal.
  • Testing for Helicobacter pylori is discussed in that article. As about 90% of duodenal ulcers and 70 to 75% of gastric ulcers are associated with this infection, testing is well worthwhile. Patients taking NSAIDs have 2 to 4 times the risk of ulceration if H pylori is positive.5 Testing patients for H pylori and eradication before starting NSAIDs reduces the incidence of ulcers.6
  • Barium meal and follow through has been largely superseded by endoscopy.
  • The NICE guidelines on Management of Dyspepsia in Adults states that endoscopy is not required unless the patient is presenting for the first time above the age of 55 or unless there are other warning signs. "Warning signs include: GI bleeding, dysphagia, unintentional weight loss, abdominal swelling and persistent vomiting."1
  • Irrespective of age endoscopy is required if there are any of the warning signs of iron deficiency anaemia or any sign of chronic blood loss, weight loss, progressive dysphagia, persistent vomiting, an epigastric mass or suspicious barium meal. In patients over 55, referral should be considered if there is previous gastric ulcer, previous gastric surgery, pernicious anaemia, NSAID use or family history of gastric carcinoma.1

Peptic ulcer is rare without the presence of H pylori or the use of NSAIDs.7

Management

Drugs used in dyspepsia and peptic ulcer disease are discussed more fully elsewhere. In particular, this article is recommended for advice about H pylori eradication regimens.8

Modification of behaviour

  • If drugs are the cause then they should be stopped or replaced if possible but this may not be possible. Being more meticulous about the instructions for taking alendronate or taking NSAIDs including aspirin after food may be required.
  • There has been no need for "ulcer diets" since the introduction of effective acid suppression but reduction of alcohol intake, coffee and spicy foods may require attention.
  • Cessation of smoking should be advised if applicable. Smoking increases the risk of peptic ulcer and delays healing as well as opposing the action of H2 antagonists. It has many effects on other parts of the gut including facilitating gastro-oesophageal reflux.
  • The new COX2 inhibitors are less likely to cause ulcers than NSAIDs9 but it is dangerous to assume that they have no risk. This advantage is nullified if the patient also takes even low dose aspirin.

Healing ulcers

Clinical Knowledge Summaries recommend that if an ulcer is proven but H pylori testing is negative, then acid suppression at full dose should be offered for 1 or 2 months.10 A lower maintenance dose may be continued after. The full course should be taken as there is little correlation between the relief of symptoms and the healing of ulcers and if medication is stopped too soon the ulcer will relapse.

  • Acid suppression at full dose PPI for 1 month or 2 will usually heal the ulcer.
  • A policy of test for H pylori and eradication if found without endoscopy is acceptable if there are no warning signs.1 This is in addition to acid suppression.
  • If NSAIDs are used, stop them if possible and give full dose PPI for 2 months.1
  • Adding eradication to acid suppression in ulcers associated with NSAIDs does not improve the rate of healing at 4 or 8 weeks but it does reduce the incidence of recurrence. NICE suggest acid suppression for 2 months before eradication. There is a suggestion that eradication may delay healing of NSAID associated ulcers5 but this is disputed.11
  • The management of peptic ulcer disease not related to H pylori or NSAIDs has been described in a review5 and in the NICE guidelines.1 If H pylori was negative, give 1 or 2 months of PPI and look for other causes.12

Management of recurrence and its prevention

  • For gastric ulcer with H pylori infection, NICE recommends eradication therapy followed by proof of eradication and repeat endoscopy. This is a consensus statement. If eradication is successful but the ulcer unhealed then malignancy needs to be considered.
  • If recurrence occurs after H pylori eradication therapy and the test is still positive this suggests failure of eradication. Therapy should be repeated with different antibiotics. Serology tests are applicable only for initial diagnosis as they remain positive for a long while.
  • If patients are to be given long term NSAIDs a review from Hong Kong suggested that stratification of risk should be used to decide the plan for prevention and that all such patients should be checked for H pylori infection.13
  • Misoprostol may also give protection against ulcers but it appears less effective than PPI and with the required dose it often produces diarrhoea.14 A Cochrane review suggests that 800mg daily is required to be effective.15 H2 antagonists are also less effective than PPIs.16
  • For patients who have relapses, intermittent therapy and annual review is recommended.1
Effectiveness of interventions

The NICE guidelines give the following data on the effectiveness of interventions based on a number of sources:

  • In duodenal ulcer, acid suppression for 4 to 8 weeks produces healing of the ulcer in 69%. This rises by an extra 5.4% with eradication therapy too. NNT=18.
  • In duodenal ulcer relapse at 3 to 12 months after treatment is 39% after short term acid suppression alone but eradication increases this by 52% to 91%. NNT=2.
  • In gastric ulcer, supplementation of acid suppression with eradication therapy does not improve healing rates but it does reduce relapse so that 3 to 12 months later 45% are free of ulcers after just acid suppression but eradication raises this by 32% to 77%. NNT=3.
  • In patients taking NSAIDs, eradication did not improve ulcer healing rate but it did halve the number of endoscopically proven ulcers 6 months later from 18 to 9%.
Complications
  • Haematemesis or melaena are associated with erosion of a large blood vessel and significant haemorrhage. Urgent admission to hospital is required. In patients whose ulcers have bled, eradication of H pylori is more effective than even long term acid suppression without eradication.17
  • Perforation of a peptic ulcer causes an acute abdomen with epigastric pain that may progress to generalised rigidity. In the presence of steroids the symptoms of perforation may be suppressed or absent.
  • Scarring of the duodenum may lead to pyloric stenosis with vomiting and weight loss but this is rare these days with effective treatment. The classical feature is that the vomit shows food such as tomato skins that were eaten 12 to 24 hours ago.
  • H pylori is not associated with an increased risk of ulcer with NSAIDs in the elderly but there is an increased risk of bleeding.18
Prognosis

Prognosis is excellent if the underlying cause such as H pylori infection or drugs can be addressed. The eradication of H pylori has led to a very substantial decrease in the rate of recurrence of ulcers. A study from Japan19 showed that annual recurrence rates of gastric, duodenal and gastroduodenal ulcer were 2.3%, 1.6%, and 1.6%, respectively. Excluding patients who took NSAIDs dropped the recurrence rates to 1.9%, 1.5% and 1.3%, respectively. The recurrence rate was significantly higher in gastric ulcer. Recurrence rates of patients who smoked, consumed alcohol, and used NSAIDs were significantly higher in those with gastric ulcer recurrence compared to duodenal ulcer. Relapsed ulcers tended to recur at the same or adjacent sites as the previous ulcers.

Changing face of peptic ulcer disease

Even within the professional lifetime of many doctors still in practice, there has been an enormous change in the management of peptic ulcer disease. The state of the art in the 1970s was unrecognizable compared with today.

  • Diagnosis was by barium meal and follow through. Now endoscopy has almost entirely replaced this.
  • Advantages of endoscopy include:
    • Direct vision of the ulcer via the endoscope rather than looking at the shadows of radiology
    • Ability to see the inflammation of gastritis or oesophagitis
    • Ability to biopsy suspicious lesions
    • Ability to take samples for culture of H pylori
    • No radiation
  • Treatment was with antacids that gave some relief of short duration.
  • If treatment with rather ineffectual antacids was unsuccessful, surgery was considered.
  • This was major abdominal surgery. A number of procedures were used.
    • Polya or Billroth II gastrectomy involved removal of about half to two thirds of the stomach
    • Vagotomy involved severing the trunk of the vagus nerves to the stomach. It had to be accompanied by pyloroplasty to facilitate gastric emptying or there would be stasis
    • Highly selective vagotomy required great skill to divide only the relevant vagal fibres to the stomach and in doing so it was unnecessary to perform a pyloroplasty too. Failure to divide all the fibres would result in failure of the operation and dividing too many without pyloroplasty would cause stasis.
  • The H2 antagonists were revolutionary in providing effective acid suppression and the need for surgery was markedly reduced.
  • They were followed by the PPIs that produced more profound suppression of longer duration.
  • The discovery of the link to H pylori enabled cure to be achieved as even the H2 antagonists and PPIs needed to be continued at low dose long term to prevent relapse.
  • A better understanding of the place of H pylori eradication, acid suppression and the possible role of the new COX2 inhibitors has made the prescription of drugs for osteoarthritis in the elderly much safer.

Patients who have had such operations for peptic ulcer may still be seen today and the long term effects of these operations need to be known.

  • A stomach of much reduced size can cause difficulty in obtaining adequate nutrition. Young people, especially young women were much at risk.
  • Inadequate production of intrinsic factor can result in pernicious anaemia.
  • There is an increased risk of tuberculosis.
  • With vagotomy and pyloroplasty in particular there were problems of early and late dumping syndrome.
  • Blind loop syndromes cause abnormal gut flora and malabsorption.
  • Bile can reflux into the stomach. A reversal operation such as the Roux-en-Y may be required.
  • Various forms of malabsorption and intestinal hurry may result.

If patients have had one of these operations 30 years or longer ago, they will have missed H pylori eradication and if it has not been done since, it is worth doing now.


Document references
  1. Dyspepsia: Managing dyspepsia in adults in primary care, NICE (2004)
  2. Kang JY, Tinto A, Higham J, et al; Peptic ulceration in general practice in England and Wales 1994-98: period prevalence and drug management. Aliment Pharmacol Ther. 2002 Jun;16(6):1067-74. [abstract]
  3. Bardhan KD, Williamson M, Royston C, et al; Admission rates for peptic ulcer in the trent region, UK, 1972--2000. changing pattern, a changing disease? Dig Liver Dis. 2004 Sep;36(9):577-88. [abstract]
  4. Lu CL, Chang SS, Wang SS, et al; Silent peptic ulcer disease: frequency, factors leading to "silence," and implications regarding the pathogenesis of visceral symptoms.; Gastrointest Endosc. 2004 Jul;60(1):34-8. [abstract]
  5. Hawkey CJ, Tulassay Z, Szczepanski L, et al; Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study. Helicobacter Eradication for Lesion Prevention. Lancet. 1998 Sep 26;352(9133):1016-21. [abstract]
  6. Chan FK, Sung JJ, Chung SC, et al; Randomised trial of eradication of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers.; Lancet. 1997 Oct 4;350(9083):975-9. [abstract]
  7. Bandolier; Peptic ulcer is rare without H pylori or NSAID
  8. de Boer WA, Tytgat GNJ; Treatment of Helicobacter pylori infection (Regular review) BMJ 2000 320: 31-34
  9. Silverstein FE, Faich G, Goldstein JL, et al; Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.; JAMA. 2000 Sep 13;284(10):1247-55. [abstract]
  10. Dyspepsia - proven DU, GU, or NSAID-associated ulcer, Clinical Knowledge Summaries (2005)
  11. Chan FK, Sung JJ, Suen R, et al; Does eradication of Helicobacter pylori impair healing of nonsteroidal anti-inflammatory drug associated bleeding peptic ulcers? A prospective randomized study. Aliment Pharmacol Ther. 1998 Dec;12(12):1201-5. [abstract]
  12. Quan C, Talley NJ; Management of peptic ulcer disease not related to Helicobacter pylori or NSAIDs. Am J Gastroenterol. 2002 Dec;97(12):2950-61. [abstract]
  13. Chan FK, Graham DY; Review article: prevention of non-steroidal anti-inflammatory drug gastrointestinal complications--review and recommendations based on risk assessment. Aliment Pharmacol Ther. 2004 May 15;19(10):1051-61. [abstract]
  14. Hawkey CJ, Karrasch JA, Szczepanski L, et al; Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. N Engl J Med. 1998 Mar 12;338(11):727-34. [abstract]
  15. Rostom A, Dube C, Wells G, et al; Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database Syst Rev. 2002;(4):CD002296. [abstract]
  16. Yeomans ND, Tulassay Z, Juhasz L, et al; A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group. N Engl J Med. 1998 Mar 12;338(11):719-26. [abstract]
  17. Gisbert JP, Khorrami S, Carballo F, et al; H. pylori eradication therapy vs. antisecretory non-eradication therapy (with or without long-term maintenance antisecretory therapy) for the prevention of recurrent bleeding from peptic ulcer. Cochrane Database Syst Rev. 2004;(2):CD004062. [abstract]
  18. Cullen DJ, Hawkey GM, Greenwood DC, et al; Peptic ulcer bleeding in the elderly: relative roles of Helicobacter pylori and non-steroidal anti-inflammatory drugs.; Gut. 1997 Oct;41(4):459-62. [abstract]
  19. Miwa H, Sakaki N, Sugano K, et al; Recurrent peptic ulcers in patients following successful Helicobacter pylori eradication: a multicenter study of 4940 patients. Helicobacter. 2004 Feb;9(1):9-16. [abstract]

Internet and further reading Acknowledgements EMIS is grateful to the Mentor authoring team for writing this article. The final copy has passed scrutiny by the independent Mentor GP reviewing team. ©EMIS 2008.
DocID: 3105
Document Version: 23
DocRef: bgp25959
Last Updated: 19 Jul 2007
Review Date: 18 Jul 2009






















Disclaimer: Patient UK has no control of the content of the above links. Inclusion does not imply endorsement by Patient UK.

Advertise on this site










Disclaimer: Patient UK has no control of the content of the above links. Inclusion does not imply endorsement by Patient UK.

Advertise on this site


PS - Health and Poverty

Perhaps the biggest cause of ill health in the world is poverty. Help to Make Poverty History. For example, why not lend some of your money to disadvantaged communities to enable them to trade their way out of poverty through schemes such as Shared Interest.

See also MAKEPOVERTYHISTORY North East for details and links to campaigns against poverty.

^ Top of Page